A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic ObstructiveInterventions:   Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg;   Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg;   Drug: Umeclidinium 62.5 mcg;   Device: Placebo ELLIPTA inhaler;   Drug: Albuterol/SalbutamolSponsor:   GlaxoSmithKlineNot yet recruiting - verified April 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials